Blog Archives

First ever treatment for Lambert-Eaton myasthenic syndrome (LEMS) FDA approved

December 04, 2018 –  The American Food and Drug Administration (FDA) has just approved its first ever treatment, Amifampridine (Firdapse), for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder for adult patients. LEMS affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. 

Read more ›

Tags: , , , , , ,

Neural tube defects with Dolutegravir-based HIV medications

May 22, 2018 –The American Food and Drug Administration (FDA) just released a Safety Alert concerning serious neural tube defects that might arise in babies born to women who took HIV medications that contained the active ingredient Dolutegravir. Neural tube defects are birth defects that can occur early in pregnancy when the spinal cord,

Read more ›

Tags: , , , , , , ,

Dabrafenib/Trametinib-Combo approved for BRAF-positive anaplastic thyroid cancer

 

May 05, 2018 – The American Food and Drug Administration (FDA) just approved the combination of Dabrafenib (Tafinlar)/Trametinib (Mekinist) to be administered together for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic),

Read more ›

Tags: , , , , , , , , ,

eHealth: Viz.AI Contact App to alert for stroke in patients

February 15, 2018 – The American Food and Drug Administration (FDA) just permitted marketing of the Viz.AI Contact application, a type of clinical decision support software designed to analyze computed tomography (CT) results that may notify providers of a potential stroke in their patients.

Read more ›

Tags: , , , , , , ,

Lutetium 177 dotatate (Lutathera): A treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

January 29, 2018 – Gastroenteropancreatic neuroendocrine tumors (GEP-NET)s are a rare group of cancers with limited treatment options that affects primarily the pancreas or gastrointestinal tract of patients.  

The American Food &

Read more ›

Tags: , , , , , , ,

Vemurafenib (Zelboraf) for BRAF V600E positive Erdheim-Chester Disease (ECD)

Dezember 21, 2017 – Erdheim–Chester disease ((ECD), also known as Erdheim–Chester syndrome or polyostotic sclerosing histiocytosis) is a form of a bone marrow borne blood cancer. It is a rare disease characterized by the abnormal multiplication of a specific type of white blood cells called histiocytes,

Read more ›

Tags: , , , , , , , , ,

Are there life-threatening health problems with Limbrel?

November 22, 2017 – Limbrel (Flavocoxid) is a medical food. A medical food is a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements,

Read more ›

Tags: , , , , , , , , , , , , , , , ,

Febuxostat (Uloric): Gout medication with increased risk for heart-related death?

November 19, 2017 – Gout is a terrible condition for those affected. Gout is a form of inflammatory arthritis characterized by recurrent attacks of a red, tender, hot, and swollen joint. Pain typically comes on rapidly in less than twelve hours. The joint at the base of the big toe is affected in about half of cases. 

Read more ›

Tags: , , , , , , , , , , ,

Black Gorilla, Big N Hard, Rize N Shine, and the likes: Fraudulent health business

November 05, 2017 – The commercial names are creative, no doubt, and we like particularly “Black Gorilla”. However, time and time again, health authorities all over have to issue foreign product alerts, warning consumers, patients, and the public at large about products that claim to be “all natural”

Read more ›

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Is there a risk of melanoma with erectile dysfunction drugs?

November 01, 2017 – According to the watch list of the American Food & Drug Administration (FDA) for drugs with possible safety issues from January to March 2016,

the FDA was looking at the possible link between various drugs in the phosphodiesterase-5 (PDE-5) inhibitors class and melanoma as a serious adverse effect.

Read more ›

Tags: , , , , , , , , , , , , , , ,

thasso: community

thasso: conditions

thasso post: magazine

View my Flipboard Magazine.

thasso: chat

You must be a registered user to participate in this chat.

thasso: tweets

thasso: categories

thasso: archives

Top